Skip to main content
. 2020 Mar;8(5):240. doi: 10.21037/atm.2020.03.21

Table 2. Therapy characteristics.

Therapy characteristics N=112
Prior systemic regimens, n (%)
   0 8 (7.1)
   1 31 (27.7)
   2 21 (18.8)
   3 17 (15.2)
   4 13 (11.6)
   5 9 (8.0)
   ≥6 13 (11.6)
Type of prior systemic regimens, n (%)
   Anthracycline-based 79 (70.5)
   Taxane-based 102 (91.1)
   Platinum-based 45 (40.2)
   Fluorouracil-based 54 (48.2)
   Endocrinotherapy 38 (33.9)
   Trastuzumab 100 (89.3)
Combined regimen of lapatinib, n (%)
   Capecitabine 78 (69.6)
   Paclitaxel weekly 21 (18.8)
   Vinorelbine 7 (6.3)
   Others 6 (5.4)